ERBB2 and breast carcinoma: They described the mAb-drug conjugates with an introduction of mAb-based therapeutics such as CD20 (Rituxan for B-cell lymphoma), HER2 (Herceptin for breast cancer), VEGF (Avastin for colon, lung, breast, and renal cancer), and EGFR (Erbitux for colon and lung cancer).